Charles Erlichman1. 1. Department of Oncology, Mayo Clinic Cancer Center, 200 First Street SW, Rochester, MN 55905, USA. erlichman.charles@mayo.edu
Abstract
BACKGROUND: Heat shock protein 90 (HSP90) is the core of a multi-chaperone complex critical for the folding, trafficking, and stabilization of many client proteins that are involved in tumor cell proliferation, survival, and angiogenesis. Targeting HSP90 results in degradation of these client proteins. OBJECTIVE: Data supporting the development of tanespimycin, which targets HSP90, are reviewed. METHODS: Clinical data available for tanespimycin development are presented. RESULTS: Tanespimycin can be given safely at biologically active doses with mild toxicity such as nausea, vomiting, diarrhea, and fatigue. Although single-agent studies have shown limited activity, combinations of tanespimycin with bortezomib or trastuzumab have suggested promising avenues of further evaluation in multiple myeloma and breast cancer, respectively. CONCLUSIONS: Further development of HSP90-targeted strategies include testing of novel chemical structures having better solubility and stability and the potential for oral administration. Targeting of HSP90 in combination with other heat shock proteins, such as HSP70 or HSP27, may be an alternative strategy that warrants further exploration.
BACKGROUND:Heat shock protein 90 (HSP90) is the core of a multi-chaperone complex critical for the folding, trafficking, and stabilization of many client proteins that are involved in tumor cell proliferation, survival, and angiogenesis. Targeting HSP90 results in degradation of these client proteins. OBJECTIVE: Data supporting the development of tanespimycin, which targets HSP90, are reviewed. METHODS: Clinical data available for tanespimycin development are presented. RESULTS:Tanespimycin can be given safely at biologically active doses with mild toxicity such as nausea, vomiting, diarrhea, and fatigue. Although single-agent studies have shown limited activity, combinations of tanespimycin with bortezomib or trastuzumab have suggested promising avenues of further evaluation in multiple myeloma and breast cancer, respectively. CONCLUSIONS: Further development of HSP90-targeted strategies include testing of novel chemical structures having better solubility and stability and the potential for oral administration. Targeting of HSP90 in combination with other heat shock proteins, such as HSP70 or HSP27, may be an alternative strategy that warrants further exploration.
Authors: Hakan Kaya; Benjamin Peressini; Irfan Jawed; Danko Martincic; Ameer L Elaimy; Wayne T Lamoreaux; Robert K Fairbanks; Kevin A Weeks; Christopher M Lee Journal: Int J Hematol Date: 2011-12-09 Impact factor: 2.490
Authors: Mackenzie D Martin; Laurent Calcul; Courtney Smith; Umesh K Jinwal; Sarah N Fontaine; April Darling; Kent Seeley; Lukasz Wojtas; Malathi Narayan; Jason E Gestwicki; Garry R Smith; Allen B Reitz; Bill J Baker; Chad A Dickey Journal: ACS Chem Biol Date: 2015-01-30 Impact factor: 5.100
Authors: Carlos L Arteaga; Mark X Sliwkowski; C Kent Osborne; Edith A Perez; Fabio Puglisi; Luca Gianni Journal: Nat Rev Clin Oncol Date: 2011-11-29 Impact factor: 66.675
Authors: Catherine J Huntoon; Monica D Nye; Liyi Geng; Kevin L Peterson; Karen S Flatten; Paul Haluska; Scott H Kaufmann; Larry M Karnitz Journal: Cancer Res Date: 2010-09-14 Impact factor: 12.701